A clinical explainer on the difference between oral and intravenous vitamin delivery — first-pass metabolism, transporter saturation, and why a 1000mcg B12 tablet is not the same as a 1000mcg B12 push.
Most consumers assume a 1000mcg B12 tablet delivers 1000mcg of B12 to their cells. It does not. Cyanocobalamin and methylcobalamin tablets have an oral bioavailability of roughly 1-2% in healthy adults — meaning 980-990mcg of every 1000mcg dose is excreted unchanged or destroyed in transit. The remaining 10-20mcg has to compete with everything else your gut is absorbing that hour.
Three independent barriers cause this loss: gastric acid degradation, intrinsic factor saturation in the terminal ileum, and first-pass metabolism in the liver. IV delivery bypasses all three. A 1000mcg IV push produces a plasma concentration roughly 50-100x higher than the equivalent oral dose, measurable within minutes.
Every nutrient absorbed from your gastrointestinal tract travels through the hepatic portal vein to the liver before entering systemic circulation. The liver's job is to filter, metabolize, conjugate and frequently destroy a large fraction of what arrives. This is 'first-pass metabolism,' and it is the single biggest reason oral bioavailability is so often disappointing.
Vitamin C is partially cleared on first pass, B-vitamins are converted to their active forms (with significant losses), and fat-soluble vitamins are repackaged into chylomicrons. IV delivery enters the systemic circulation directly via a peripheral vein, bypassing the portal system entirely. Your cells see the full dose at the full concentration — exactly what the prescribing clinician intended.
Vitamin C is the textbook example. Oral vitamin C is absorbed by sodium-dependent vitamin C transporters (SVCT1) in the small intestine. These transporters saturate at roughly 200mg per dose. Above that threshold, additional vitamin C passes through without absorption — which is why 1g and 5g oral doses produce nearly identical plasma concentrations (around 70-80 μmol/L) and the rest exits in urine.
An IV push of 25g vitamin C, by contrast, can produce plasma concentrations of 15,000-20,000 μmol/L — pharmacologic, not nutritional, levels. This is why high-dose IV vitamin C is studied for oncology adjunct protocols while oral high-dose vitamin C is not. The route, not the dose, is what changes.
Oral magnesium absorption sits at 30-40% in healthy adults for citrate and glycinate forms, dropping to 4-10% for oxide (the cheapest and most-sold form). Even at best, a 400mg oral magnesium dose delivers ~120-160mg systemically — and a meaningful fraction of that produces the laxative effect rather than tissue repletion.
An IV magnesium chloride infusion at the Myers Cocktail dose (roughly 200-400mg elemental magnesium) delivers 100% of the labeled dose. This matters clinically because intracellular magnesium repletion takes weeks of consistent oral dosing and can be achieved in a single IV session. For travelers with limited time, athletes after heavy training loads, or anyone with established magnesium-related symptoms (muscle cramps, sleep disturbance, migraine), the route makes a measurable difference.
The Myers Cocktail combines exactly the nutrients where the oral-to-IV bioavailability gap is widest: B12 (1-2% oral vs 100% IV), magnesium (4-40% oral vs 100% IV), vitamin C (saturable oral transporter vs unlimited IV), B-complex (variable first-pass losses vs full systemic delivery) and calcium (~25% oral vs 100% IV). This is why a single Myers infusion can produce subjective effects within hours that weeks of equivalent oral supplementation cannot reliably reproduce.
Read our pillar guide for the full clinical breakdown, or our Myers vs NAD+ comparison if you're deciding which IV protocol is right for your goal.
IV therapy is not a replacement for daily nutrition or long-term oral supplementation. For sustained vitamin D, omega-3, iron and most basal nutrient needs, oral is the correct route — IV exists for acute repletion, symptom relief, and clinical scenarios where the gut is bypassed or the timeline demands it.
The clinical decision is: are you trying to maintain a baseline (oral) or rapidly correct a deficit / produce a measurable physiological effect today (IV)? Both routes have a place. The honest framing is route-appropriate dosing, not 'IV is always better.'